Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria
| Autor: | Joichi Kumazawa, Mikinobu Ohtani, Kimio Fujita, Naoto Miyanaga, Koji Obata, Yoshihiko Hirao, Kazuki Kawabe, Hideyuki Akaza, Kenkichi Koiso, Satoru Ishikawa, Hiroyuki Ohmori, Noguchi R, Yoshinobu Kubota, Toshihiko Kotake, Taiji Tsukamoto |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Urinalysis Urology Urinary system Prostatic Hyperplasia Urine urologic and male genital diseases Diagnosis Differential Prostate cancer Cystitis Biomarkers Tumor Humans Mass Screening Medicine Microscopic hematuria Mass screening Aged Hematuria Urine cytology Aged 80 and over medicine.diagnostic_test business.industry Nuclear Proteins Prostatic Neoplasms Cystoscopy Middle Aged medicine.disease Urinary Bladder Neoplasms Female Urinary Calculi Urothelium business |
| Zdroj: | International Journal of Urology. 6:173-177 |
| ISSN: | 1442-2042 0919-8172 |
| Popis: | Purpose: The aim of the present study was to determine the clinical usefulness of nuclear matrix protein 22 (NMP22) as a new urinary marker for the screening of urothelial cancer in patients with microscopic hematuria, especially in comparison with that of voided urine cytology. Methods: Patients with microscopic hematuria detected at a health examination, who were advised by a consulted urologist to have a cystoscopical examination, were asked to enter this study. Urine samples were collected before cystoscopy and divided into two portions for a NMP22 test and voided urine cytology. Results: Of the 309 patients with microscopic hematuria, 22 cases (7.1%) of urothelial cancer and one case of prostate cancer were detected. For the other cases, 128 (41.4%) were of benign diseases and 158 (51.1%) were designated as having no evidence of disease (NED). The median NMP22 values for urothelial cancer, other diseases and NED were 35.5, 6.7 and 6.0 U/mL, respectively, with 95% confidence intervals of 19.9–228.2, 5.1–9.3 and 5.4–7.2, respectively. The sensitivity of the NMP22 test for urothelial cancer was 90.9% (20/22), whereas the sensitivity of voided urine cytology was only 54.5% (12/22). Conclusions: The present study indicates that urinary NMP22 is a useful tool for the screening of urothelial cancer in patients with microscopic hematuria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|